ANI Pharmaceuticals (NASDAQ:ANIP) CFO Stephen Carey Sells 3,312 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 3,312 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.00, for a total value of $264,960.00. Following the transaction, the chief financial officer directly owned 180,393 shares of the company’s stock, valued at approximately $14,431,440. This trade represents a 1.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $81.20 on Wednesday. The stock has a fifty day simple moving average of $79.35 and a two-hundred day simple moving average of $79.37. ANI Pharmaceuticals, Inc. has a 1-year low of $61.17 and a 1-year high of $99.50. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of 20.56 and a beta of 0.44. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. During the same period in the prior year, the company earned $1.70 earnings per share. ANI Pharmaceuticals’s revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ANIP has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, June 1st. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $107.33.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Maryland State Retirement & Pension System boosted its stake in ANI Pharmaceuticals by 5.4% during the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock valued at $206,000 after buying an additional 134 shares during the period. The Manufacturers Life Insurance Company boosted its stake in ANI Pharmaceuticals by 1.5% during the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after buying an additional 143 shares during the period. Illinois Municipal Retirement Fund boosted its stake in ANI Pharmaceuticals by 1.7% during the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock valued at $782,000 after buying an additional 145 shares during the period. CANADA LIFE ASSURANCE Co boosted its stake in ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after buying an additional 198 shares during the period. Finally, Oregon Public Employees Retirement Fund boosted its stake in ANI Pharmaceuticals by 5.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock valued at $323,000 after buying an additional 200 shares during the period. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.